AIBioTech Announces The Addition Of Kristine L. Bucasas, Ph.D. As Group Leader Of Clinical Services

Richmond, VA – AIBioTech is proud to announce the addition of Kristine L. Bucasas, Ph.D. as group leader of clinical services.

As group leader of clinical services, Bucasas will direct the clinical operations and help ensure laboratory quality and compliance to regulatory bodies. She will also direct activities of several clinical and scientific groups in the research and development of new products and programs, in relation to bringing technological developments on molecular diagnostics and therapeutics to the clinical market.

"It is a pleasure having Dr. Bucasas as a member of our team. She is a wonderful addition to our company as we continue to expand our products and services to the clinic", said AIBioTech Vice President of DNA Services Greg Meyers.

"I look forward to working together with different AIBioTech groups as a team, and in contributing towards bringing the vision of the company into reality", said Bucasas.

Bucasas comes to AIBioTech with a background in immunology from Baylor College of Medicine in Houston, Texas. She is also the author of scientific peer-reviewed publications and has been a recipient of National Institutes of Health fellowship grants.

About AIBioTech

AIBioTech is a comprehensive contract research organization which provides clinical testing and research and development services to physicians and life science investigators in biotechnology and pharmaceutical companies, academic institutions, and in several different government agencies. It also operates a forensics and paternity testing division under the name Fairfax Identity Laboratories. For more information about its capabilities and services visit the company website at www.aibiotech.com.

Jenn Cleary

Marketing Assistant

601 Biotech Drive

Richmond, VA 23235

Phone: (804) 648-3820 ext: 1631

Fax: (804) 648-2641

Email: [email protected] 

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.